Detalhe da pesquisa
1.
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
J Virol
; 92(2)2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29093095
2.
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Clin Infect Dis
; 62(11): 1329-1335, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001804
3.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Vaccine
; 41(15): 2615-2629, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925422
4.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Vaccine
; 41(45): 6762-6773, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37739888
5.
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
J Infect Dis
; 204(9): 1395-402, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21921208
6.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Vaccine
; 40(35): 5263-5274, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35715351
7.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Vaccine
; 40(35): 5275-5293, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35753841
8.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 40(35): 5248-5262, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35715352
9.
Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
J Infect Dis
; 202(4): 595-605, 2010 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20608874
10.
The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
Vaccine
; 39(19): 2712-2718, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33846042
11.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Vaccine
; 39(38): 5436-5441, 2021 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373117
12.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 39(22): 3081-3101, 2021 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676782
13.
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Vaccine
; 39(22): 3053-3066, 2021 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637387
14.
A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
J Clin Invest
; 131(5)2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33529172
15.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Vaccine
; 38(49): 7708-7715, 2020 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32907759
16.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Vaccine
; 38(34): 5556-5561, 2020 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32571717
17.
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Vaccine
; 38(49): 7702-7707, 2020 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070999
18.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Vaccine
; 38(35): 5734-5739, 2020 07 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653276
19.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine
; 38(39): 6184-6189, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32747214
20.
Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.
Vaccine
; 37(11): 1389-1397, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30772070